GE Healthcare Announces Commercial Availability of New Methodology That...
(Source: GE - General Electric Company) --Groundbreaking method uses quantitative protein analysis to identify new biosignatures, for personalized treatments-- PRINCETON, NJ, May 31, 2013 - GE...
View ArticleGE Healthcare Announces Commercial Availability of New Methodology That...
GE Healthcare today announced at the 2013 Annual Meeting of the American Society of Clinical Oncology its plans for the commercialization of MultiOmyx™, a ground-breaking new pathology platform, using...
View ArticleGE Healthcare Licenses Genomic Biomarker for Lung Cancer from Insight Genetics
GE’s Clarient Diagnostic Services to develop PCR-based test to identify patients who have ALK-positive lung cancers ALISO VIEJO, Calif. and NASHVILLE, Tenn.--(BUSINESS WIRE)--Clarient Diagnostic...
View ArticleBiocept and Clarient Announce Launch of Proprietary Circulating Tumor Cell...
SAN DIEGO & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and Clarient, Inc., a GE Healthcare...
View ArticleUse of Mammostrat Bioassay Predicts Early Relapse Risk in ER-Positive...
Results from TEAM Trial presented at 2012 Annual Meeting of American Society of Clinical Oncology 2012 ASCO Annual Meeting CHICAGO--(BUSINESS WIRE)--GE Healthcare today announced results from the...
View ArticleGE Healthcare to Showcase Innovative Breast Cancer Solutions from Screening...
GE Healthcare, the healthcare division of General Electric Company (NYSE:GE) is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most...
View ArticleBiocept and Clarient Announce Collaboration on First Test for Circulating...
, Aug. 24, 2011 /PRNewswire/ -- Biocept, Inc., a privately-held CLIA-certified laboratory testing company, focused on the detection and analysis of circulating tumor cells (CTCs) in cancer patients,...
View ArticleClarient, A GE Healthcare Company, Introduces First Lab Developed Test To...
MultiOmyx™ technology aids in pathologist’s diagnosis of certain difficult lymphoma cases by doing more with less tissue May provide a more complete picture of a patient’s cancer and help explain...
View ArticleClarient, A GE Healthcare Company, Introduces First Lab Developed Test To...
(Source: GE - General Electric Company) MultiOmyx™ technology aids in pathologist's diagnosis of certain difficult lymphoma cases by doing more with less tissue Paper in Proceedings of the National...
View ArticleClarient CEO Ron Andrews to Present at the Roth Annual OC Growth Stock...
ALISO VIEJO, Calif., March 8, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical...
View ArticleGE Healthcare Building a Stronger Network in the Fight Against Cancer (GE...
(Source: GE Healthcare USA Holding Inc) PITTSBURGH and ALISO VIEJO, CA, March 24, 2015 - Amidst an estimated 70 percent increase in cancer diagnosis in the next two decades and an estimated 1.41...
View ArticleClarient to Present at Upcoming Investment Conferences in New York City
ALISO VIEJO, Calif., Sept. 1 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today...
View ArticleGE Healthcare Launches its First "Next-Generation" Sequencing Assay
GE Healthcare announced today that Clarient Diagnostic Services, Inc., a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical...
View ArticleGE Healthcare Invests in FISH Technologies for Leukemia and Lymphoma Testing...
(Source: GE - General Electric Company) Interactive PATHSiTETM Virtual HemeFISH Solution Offers More Clarity for Pathologists Aliso Viejo, CA - March 4, 2014 - GE Healthcare announced today that...
View ArticleClarient to Present at William Blair Third Annual Emerging Growth Conference...
ALISO VIEJO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today...
View ArticleClarient CEO Ron Andrews to Present at the Roth Annual OC Growth Stock...
ALISO VIEJO, Calif., March 8 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today...
View ArticleClarient CEO Ron Andrews to Present at the UBS 20th Annual Global Healthcare...
ALISO VIEJO, Calif., Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical...
View ArticleClarient CEO Ron Andrews to Present at Jefferies 2010 Global Healthcare...
ALISO VIEJO, Calif., Jan 20, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical...
View ArticleClarient CEO Ron Andrews to Present at the UBS 20th Annual Global Healthcare...
ALISO VIEJO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today...
View ArticleClarient CEO Ron Andrews to Present at Jefferies 2010 Global Healthcare...
ALISO VIEJO, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today...
View ArticleClarient to Present at Two Investor Conferences in September
ALISO VIEJO, Calif., Sept 07, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists,...
View ArticleClarient to Present at Two Investor Conferences in August
ALISO VIEJO, Calif., Aug 04, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists,...
View ArticleClarient Names Neal S. Goldstein, M.D. Director of Surgical Pathology
Nationally Known Author, Thought Leader in Surgical, Molecular Pathology...
View ArticleClarient Presentation Time Change at the Baird 2010 Health Care Conference
ALISO VIEJO, Calif., Sept 09, 2010 /PRNewswire via COMTEX News Network/ -- Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists,...
View ArticleClarient Launches New Lung Cancer Test
Clarient Insight(R) Dx Pulmotype(R) Test Aids Physicians in Classifying Subtypes of Lung Cancer, Identifying Most Effective Therapy ALISO VIEJO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Clarient,...
View ArticleNew Data Indicate Effectiveness of Clarient's Pulmotax(TM) Test for Lung Cancer
Pulmotax Identifies Patients Who Respond Positively to Chemotherapy...
View ArticleGE Healthcare Invests in FISH Technologies for Leukemia and Lymphoma Testing
GE Healthcare announced today that Clarient Diagnostic Service, Inc., a GE Healthcare company, has made significant upgrades to its fluorescence in situ hybridisation (FISH) technologies to improve...
View ArticleNew Studies Show How Using GE Healthcare’s MultiOmyx™ in Hodgkin Lymphoma and...
(Source: GE - General Electric Company) Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer ALISO VIEJO, CA, December 9, 2013 - GE Healthcare today announced...
View ArticleDecember 9, 2013 New Studies Show How Using GE Healthcare’s MultiOmyx™ in...
(Source: GE Healthcare USA Holding Inc) Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer ALISO VIEJO, CA, December 9, 2013 - GE Healthcare today announced...
View ArticleNew Studies Show How Using GE Healthcare’s MultiOmyx™ in Hodgkin Lymphoma and...
ALISO VIEJO, Calif.--(BUSINESS WIRE)--GE Healthcare today announced results from two studies that show how using the MultiOmyx™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast...
View ArticleGE Healthcare Announces Commercial Availability of New Methodology That...
--Groundbreaking method uses quantitative protein analysis to identify new biosignatures, for personalized treatments-- 2013 ASCO Annual Meeting PRINCETON, N.J.--(BUSINESS WIRE)--GE Healthcare today...
View Article
